Doctor shares 5 natural weight loss hacks that don't come with dangerous side effects
GLP-1 drugs like Ozempic, Wegovy and Mounjaro have become incredibly powerful tools for weight loss. While they do suppress appetite and help people shed weight, the cost at which this comes is important to consider.
It's essential to look beyond short-term outcomes. In an interview with HT Lifestyle, Dr Kalpana Gupta Shekhawat, Functional and Metabolic Medicine Specialist, shared, 'With GLP-1 drugs, the risks are real—there have been observed cases of muscle loss, nutrient deficiencies and slower gut motility. Many individuals experience significant nausea, making it difficult to get through the day. Gallbladder issues have also been reported. In some patients, pancreatitis has developed, and early data has raised concerns about thyroid tumours in certain individuals. The long-term impact of these drugs remains uncertain.'
These are not mild side effects; they can seriously impact long-term health. Dr Kalpana Gupta Shekhawat, 'Another concern is that weight often returns once the drug is discontinued, particularly if the root causes of weight gain—such as poor diet, inflammation, insulin resistance, and stress—are not addressed. This raises the question: what are the alternatives?'
The expert advised:
One such strategy is starting the day with a source of healthy protein, which could come in the form of sprouted lentils or Greek yogurt. Starting the day with protein has shown positive effects.
Instead, to manage healthy weight, people should consider eating whole foods—whole grains, vegetables, lentils, millets, seasonal fruits and healthy fats such as avocado, ghee, olive oil, or coconut oil.
It can improve insulin sensitivity, promote fat burning and support a healthy circadian rhythm.
Gut imbalances can affect satiety hormones, increase cravings and block nutrient absorption. Incorporating fermented foods, prebiotic fibers and probiotics—while avoiding gut irritants like alcohol, excessive caffeine, processed snacks and chemically preserved foods—is recommended.
Chronic stress elevates cortisol levels, which contributes to abdominal fat and insulin resistance. Daily mindfulness practices, such as 10 minutes of deep breathing, can help regulate hormones and metabolism.
Dr Kalpana Gupta Shekhawat asserted, 'Ultimately, true health doesn't come in the form of drugs or injections. It comes from understanding the body and making consistent, nourishing choices. While GLP-1 drugs may offer a shortcut, true healing lies in long-term strategies that honor the body's natural intelligence.'
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
21 minutes ago
- Business Standard
Diabetes and obesity management drug Mounjaro sees sales rise in India
Eli Lilly's diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven by increasing demand and a growing number of patients shifting to higher dosages, according to market research firm Pharmarack. In May, volume sales of the 5 mg dose grew by 2.5 times. The drug, launched in India on 20 March this year, is currently available in two injectable dosage forms — 2.5 and 5 milligrams (mg). It is prescribed primarily for patients who meet certain clinical criteria related to obesity and diabetes. Data suggests that both value and quantity sales of the 5 mg form more than doubled from April to May, outperforming the 2.5 mg dosage. Mounjaro 5 mg sales rose from 9,380 units in April (valued at ₹3.08 crore) to 22,940 units in May, valued at ₹7.53 crore. For the 2.5 mg form, demand growth was relatively muted — 19,350 units in May, up from 18,270 units in April. The sales value for May stood at ₹5.08 crore, up marginally from ₹4.8 crore the previous month. However, the steady growth in the 2.5 mg dosage indicates a consistent rise in new patients starting the drug. Patients typically begin treatment with the 2.5 mg dose, which is gradually escalated. 'The almost doubling of sales for the 5 mg form is because existing patients are upgrading to higher doses after four weeks, while new patients are also onboarding Mounjaro in good numbers,' said Sheetal Sapale, vice-president (commercial) at Pharmarack. Treatment with Mounjaro is typically initiated with the lowest available dosage (2.5 mg), administered subcutaneously once a week. 'This starting dose is usually maintained for the first four weeks to help the patient adjust and minimise potential side effects,' said Dr Sukhvinder Singh Saggu, director for minimal access, GI and bariatric surgery at CK Birla Hospital, Delhi. After this initial phase, the dose is commonly increased to 5 mg weekly, as weight-loss outcomes tend to be more pronounced at this level. Experts add that while the 2.5 mg dose helps initiate the process, many patients experience a plateau at that dosage, and shifting to 5 mg allows for more consistent and promising results. Doctors say inquiries for the drug have risen steadily, with Mounjaro now also being prescribed in select cases prior to bariatric surgery. Saggu said many new patients are actively inquiring about the drug, either as a new treatment option or as part of their ongoing weight management plans. 'Some of our existing patients, who were previously prescribed medications like Fenoglide, are now also being considered for Mounjaro as an alternative or add-on therapy,' he added. According to standard guidelines for obesity management medications (OMMs), a patient must have a Body Mass Index (BMI) over 27 with at least one obesity-related comorbidity, such as Type 2 diabetes, hypertension, or high cholesterol. However, doctors are also receiving inquiries from individuals who do not meet the medical criteria. 'We are strictly discouraging its use for cosmetic purposes or in patients who do not meet the clinical threshold,' Saggu said.
NDTV
an hour ago
- NDTV
Ozempic Side-Effect: Male Users Claim Shocking Change After Taking Weight Loss Drug
Men using Ozempic, a popular weight-loss injection, have reported an unexpected side effect - an increase in perceived penis size. Numerous users have taken to online forums and social media platforms to share their experiences, claiming that their private parts appear larger since starting the medication. While anecdotal, these claims have sparked lively conversations, with dozens of men attributing their enhanced confidence and physical changes to the drug. The phenomenon has yet to be formally studied, but it's generating buzz as a surprising potential perk of the weight-loss treatment. One person wrote on Reddit, "I recently measured myself down there and noticed I gained about one inch. Now I think people will say it was because of the fat loss. However, at the time I measured myself before (4 years ago), I was thinner. I also pressed during measurement before, and also this time. Has anyone else noticed this change in themselves?" Another Reddit user shared, "Yes. I gained 1.5 inches in length. No joke. Like you I obviously know how long I was before I got very fat. Then after about seven months on Tirzepatide in my case I gained 1.5 inches in length. Definitely not all from weight loss." Some men attributed it to improved blood flow and reduced pubic fat due to weight loss. However, a Redditor suggested that the apparent size difference might result from varying external conditions, such as temperature or arousal levels, during before-and-after measurements rather than the drug itself. "I feel like nobody is really reading what you are writing, that they blame the weight loss while you measured the first time when you were actually lighter. Ozempic does not enlarge your penis, but an erect penis may change size considerably depending on time of day, temperature, and factors other than sexual arousal. So it's probably just simply that," he explained. Other Ozempic Side Effects This is not the only side effect linked to the weight loss drug. Recently, some users reported "Ozempic teeth," characterised by various dental problems, including dry mouth, bad breath, gum disease, and tooth decay. According to reports, the drug's appetite-suppressing effect reduces food intake, which in turn decreases salivary gland stimulation. Reduced saliva flow increases the risk of cavities and gum issues. Additionally, some users experience nausea or vomiting, which can expose teeth to stomach acid, further eroding enamel. According to the New York Post, a doctor previously warned about "Ozempic mouth". The condition is marked by pronounced folds at the corners of the mouth, noticeable wrinkles on the lips, and sagging skin along the lip contours and chin area. Other complications include "Ozempic face" and "Ozempic butt". "Ozempic face" refers to the prematurely aged look some patients develop after shedding pounds at record speed. "Ozempic butt" on the other hand, refers to the saggy rear end some users are complaining about.
Mint
4 hours ago
- Mint
Not Ozempic, in India THIS weigh-loss and diabetes drug from Eli Lilly sees sales jump 60% — what is it?
While rival Ozempic has made international headlines for its weightloss use, in India, sales of weight-loss and diabetes drug Mounjaro, manufactured by pharma giant Eli Lilly, has been the big winner. Largely due to first mover advantage, sales of Mounjaro jumped 60 per cent in May 2025, compared to the previous month, according to a Bloomberg report. Notably, May was the second full month that the tirzepatide injection drug has been available to patients in India, which has the third-highest number of obese people in the world, the report added. According to data from market analysis company Pharmarack Technologies, Eli Lilly sold $1.5 million or ₹ 12.6 crore worth of Mounjaro in India in May 2025. Further, sales of the the US drugmaker's 5 mg version have more than doubled to ₹ 7.5 crore, while revenue from the 2.5 mg version was ₹ 5.1 crore, the data showed. 'The patient number may have actually doubled in May from April. The demand is gradually rising and should continue. Newer patients are being introduced with the lower dose and upgraded to 5 mg injections after four weeks,' Sheetal Sapale, VP of Pharmarack told Bloomberg News. Eli Lilly's Mounjaro is a brand-name subcutaneous injection pen, chemically known as tirzepatide. It is a weekly injectable medication for obesity and type 2 diabetes. It has been approved for sale in India by the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is notable for its dual-action mechanism, targeting both GLP-1 and GIP receptors, which enhances its effectiveness in managing blood sugar levels. According to a report by Healthline, it works by helping your body to produce more insulin when needed. It also reduces the amount of glucose, or sugar, produced by the liver, and slows down how quickly food is digested. This all helps to lower blood sugar levels and HbA1c. It increases how sensitive your body is to insulin and signals your pancreas to make more insulin after you eat. Mounjaro weekly injection is priced at ₹ 4,375 ($50.67) for a 5 mg vial and ₹ 3,500 ($40.54) for a 2.5 mg vial, its lowest doses, the company told new agency Reuters. Its highest dose is 15 mg. A patient in India may have to spend about ₹ 14,000 to ₹ 17,500 (around $200) a month when taking a weekly dose of 5 mg, subject to doctor's prescription. Biocon on June 3 recieved approval to produce Novo Nordisk's celebrated type-2 diabetes and anti-obesity drug Victoza in India. Victoza is the Norweigian pharma giant's daily dose option for Ozempic, which is administered weekly. 'It's difficult to guide on exactly when Ozempic is coming to what countries,' Camilla Sylvest, executive vice president at Novo Nordisk, said at a briefing in March 2025, addressing a question on the brand's potential India launch. While Ozempic itself has not been launched in India, its patent is quickly approaching patent expiry in January 2026, and India's top generics players such as Cipla, Dr Reddy's and Sun Pharma (besides Biocon) are rushing to develop versions of GLP-1 drugs. The main difference between Mounjaro and Ozempic lies in their active ingredients. Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors, while Ozempic contains semaglutide, which only targets GLP-1 receptors. According to Goldman Sachs, the market for GLP-1 drugs is expected to reach $100 billion by 2030. In India too, the market is considered to be vast, as the country has around 10 crore people living with diabetes and obesity each, Eli Lilly had said earlier this year. (With inputs from Agencies)
